TICKERNERD
Menu
MDGLMDGLHealthcare · Biotechnology

MDGL Stock Forecast: Madrigal Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$513
−0.79% on the day

The 17 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. hold a median 12-month price target of $652 — +27.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 69 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$11.9B
Ticker Nerd rank
69 / 100
Median analyst target
$652
Analysts covering
17
Revenue$364.3M+71.2% y/y
Operating income−$56.3M
Net income−$57.9M
Free cash flow$19.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−5.9%
YTD
−12.0%
1Y
+23.6%
From 52W high
−15.0%
From 52W low
+24.4%
$412
$603
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MDGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Madrigal Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
69 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Value
93
Quality
85
Revisions
77
Momentum
77
Growth
45
Accruals
40
Size
14
Issuance
13

Volatility (96): The share price has been relatively steady.

Issuance (13): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MDGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800$900$1,000Oct 25Jan 26Apr 26Jul 26MDGLHigh $962Median $652Low $543

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says17 analysts
16 Buy1 Hold0 Sell
Low $543Median $652High $962

The green dot is the last close — the median target sits +27.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Wolfe ResearchUpgradeOutperform$605
3 Aug 2026BarclaysMaintainsOverweight$964 → $962
29 July 2026Canaccord GenuityMaintainsBuy$578 → $587
27 July 2026Wells FargoInitiatesOverweight$685
27 July 2026Wells FargoInitiatesOverweight—
11 June 2026B of A SecuritiesMaintainsNeutral$550 → $542
11 June 2026B of A SecuritiesMaintainsNeutral—
13 May 2026Truist SecuritiesMaintainsBuy—
7 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026HC Wainwright & Co.ReiteratesBuy—
20 Feb 2026B of A SecuritiesMaintainsNeutral—
28 Jan 2026BarclaysInitiatesOverweight—
20 Jan 2026CitizensMaintainsMarket Outperform—
19 Dec 2025Piper SandlerMaintainsOverweight—
11 Dec 2025B. Riley SecuritiesMaintainsBuy—
21 Nov 2025HC Wainwright & Co.MaintainsBuy—
20 Nov 2025OppenheimerMaintainsOutperform—
19 Nov 2025Truist SecuritiesMaintainsBuy—
13 Nov 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MDGL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Madrigal Pharmaceuticals, Inc. returned +23.6% against +19.6% for the S&P 500, dividends included.

MDGL vs S&P 500, last 12 monthsTotal return, rebased to 100
100110120130140150Oct 25Jan 26Apr 26Jul 26MDGLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MDGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Madrigal Pharmaceuticals, Inc. (MDGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−40.2×

Cheaper than 98% of US stocks

Price / sales
9.3×

Cheaper than 16% of US stocks

Price / book
22.8×

Cheaper than 5% of US stocks

EV / EBITDA
−35.7×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
71.2%

Higher than 90% of US stocks

Earnings growth (YoY)
71.2%

Higher than 80% of US stocks

Gross margin
89.0%

Higher than 96% of US stocks

Operating margin
−15.5%

Higher than 23% of US stocks

Net margin
−25.3%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−53.3%

Higher than 20% of US stocks

Return on assets
−17.8%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Madrigal Pharmaceuticals, Inc. (MDGL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Madrigal Pharmaceuticals, Inc. has a market value of $11.9B and an enterprise value of $11.4B.

  • Revenue in the twelve months to 30 June 2026: $1.3B. The latest quarter grew 71.2% year on year.

  • Net income over the same four quarters: −$325.1M, a −25.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−12.89.

  • Free cash flow in the twelve months to 30 June 2026: −$209.3M.

  • Shares outstanding: 23.1M.

  • Trailing P/E: −40.2×; forward P/E: 53.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Madrigal Pharmaceuticals, Inc. employs 915 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

MDGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MDGLMadrigal Pharmaceuticals, Inc.$11.9B
69
ARWRArrowhead Pharmaceuticals, Inc.$12.2B
59
HALOHalozyme Therapeutics, Inc.$12.3B
97
TECHBio-Techne Corp.$11.3B
94
BMRNBioMarin Pharmaceutical, Inc.$12.9B
60
CORTCorcept Therapeutics, Inc.$13.1B
80
AXSMAxsome Therapeutics, Inc.$10.7B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Madrigal Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MDGL news & analysis

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 20 Aug 2026neutral

Madrigal Pharmaceuticals announced that on August 15, 2026, it granted equity inducement awards to 13 new non-executive employees under its 2025 Inducement Plan. The awards were approved by the company's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This is a routine administrative disclosure regarding employee equity grants that signals hiring activity but does not affect Madrigal's business outlook or financial performance.

Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

MarketBeat · 15 Aug 2026positive

Madrigal Pharmaceuticals reported that Rezdiffra continued strong commercial growth in the second quarter of 2026, reached a $1.3 billion run rate, and expanded its development pipeline around the MASH therapy while preparing for several potential clinical catalysts.

Why it matters — MDGL watchers would care because the report signals ongoing commercial momentum for Rezdiffra, pipeline expansion around MASH, and upcoming clinical catalysts.

Madrigal Appoints John C. Reed, M.D.

GlobeNewsWire · 12 Aug 2026neutral

Madrigal Pharmaceuticals announced the appointment of John C. Reed, M.D. The company, which focuses on developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), made the announcement on August 12, 2026.

Why it matters — A new appointment to the company's leadership or board could be relevant to MDGL watchers tracking changes in its management and strategic direction.

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Seeking Alpha · 11 Aug 2026neutral

Madrigal Pharmaceuticals presented at Canaccord Genuity's 46th Annual Growth Conference, with a transcript of the presentation published by Seeking Alpha. The item covers the company's remarks at the investor conference.

Why it matters — MDGL watchers would care because the presentation offers insight into the company's latest updates as communicated directly to investors at a major growth conference.

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 6 Aug 2026neutral

Madrigal Pharmaceuticals announced that on August 1, 2026 it granted equity inducement awards to ten new non-executive employees under its 2025 Inducement Plan. The company focuses on developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH).

Why it matters — MDGL watchers would note this compensation-related disclosure as a routine but notable administrative item tied to the company's Nasdaq listing obligations and its employee inducement plan.

FAQ

Frequently asked questions about MDGL stock

What is the MDGL stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Madrigal Pharmaceuticals, Inc. have a median 12-month price target of $652, with estimates ranging from $543 to $962. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDGL stock a buy right now?

Of the 17 analysts covering Madrigal Pharmaceuticals, Inc., 16 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Madrigal Pharmaceuticals, Inc. 69 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDGL?

As at 22 Aug 2026, Madrigal Pharmaceuticals, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will MDGL stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +27.1% from the last close, and Ticker Nerd's factor model ranks Madrigal Pharmaceuticals, Inc. 69 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDGL stock forecast for 2030?

No analyst covering Madrigal Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $543 to $962 over the next 12 months.

How has MDGL stock performed over the past year?

Madrigal Pharmaceuticals, Inc. returned +23.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Madrigal Pharmaceuticals, Inc. do?

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions.

What is the latest news on MDGL?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)". Madrigal Pharmaceuticals announced that on August 15, 2026, it granted equity inducement awards to 13 new non-executive employees under its 2025 Inducement Plan. The awards were approved by the company's independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and related liver conditions. Its lead product, Rezdiffra (resmetirom), is a liver-directed thyroid hormone receptor beta agonist approved for treating adults with MASH and moderate to advanced liver fibrosis, marking it as the first FDA-approved therapy in this category. The company has also expanded its pipeline through a global licensing agreement for ervogastat, an oral DGAT-2 inhibitor in Phase 2 development, to complement its MASH treatment offerings. Madrigal Pharmaceuticals, Inc. targets the growing demand in the metabolic liver disease market, where it plays a pioneering role with rapid commercialization efforts, including approvals in the United States and Europe. Headquartered in West Conshohocken, Pennsylvania, and founded in 2000, the company concentrates on addressing unmet needs in cardiovascular, metabolic, and liver diseases through targeted oral therapies.

CEO Mr. William J. Sibold · 915 employees · United States · https://www.madrigalpharma.com